Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 4061


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Wound Care
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4061

License Grant
The Licensee licensed, from the Licensor, the exclusive worldwide rights for human dermatological uses to a cationic, antimicrobial peptide, whose active component is omiganan pentahydrochloride. The License for omiganan provides for unrestricted rights to subLicense also subject to these terms.
Field of Use
The rights granted apply for human dermatological uses.

IPSCIO Record ID: 211926

License Grant
The Canadian Licensor grants an exclusive, royalty-bearing license under the Licensor Technology to use, market, advertise, promote, distribute, offer for sale, sell, make, manufacture, have manufactured, export and import, and develop the Product in the Territory for use in the Field with the right to sublicense.
License Property
The licensed property is patents and know-how related to the compound.  The compound is omiganan pentahydrochloride.

Omiganan pentahydrochloride (formerly MBI 226) is a novel topical cationic peptide analog of indolicidin that was originally purified from the cytoplasmic granules of bovine neutrophils.  A topical 1% gel preparation of omiganan is currently in phase III clinical trials for the prevention of catheter-related bloodstream infections

The Product means any and all pharmaceutical formulations containing any and all concentrations, sizes of volume, configurations and combinations of the Compound.

Field of Use
Field means the topical administration to a burn site or a surgical wound site for the treatment or prevention in humans or burn-related or surgery-related infections, and topical administration to a device or a site around the device for the treatment or prevention in humans of device-related infections, including LCSI or  local catheter site infection and CRBSI or catheter related blood stream infection.

IPSCIO Record ID: 2678

License Grant
The Canadian University granted the Licensee an exclusive, worldwide License to use and subLicense certain defined Technology comprised primarily of three broad patents for antimicrobial peptides and related methods of use and any improvements within a specified field of use and including the right to manufacture, distribute and sell products utilizing the Technology.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any Improvements solely within the Field of Use. The Licensee will furnish the University with a copy of each sublicense granted within 30 days after execution.

License Property
98-005 USA 09/143,124 Anti-Endotoxic , Antimicrobial Hancock, REW 8/28/98 Cationic Peptides and Methods of Use Gough, M Therefor Patrzykat, A Woods, D Jia X

98-005 PCT WO 00/12528 Anti-Endotoxic , Antimicrobial As above 8/27/99 Cationic Peptides and Methods of Use Therefor

98-006 USA 6,172,185 Antimicrobial Cationic Peptide Hancock, REW Issued Derivatives of Bactenecin Wu, M 1/9/01

00-005 USA 09/604,864 Antimicrobial Peptides and Methods of Hancock, REW 7/27/00 Use Thereof Zhang, L.

Field of Use
'Field of Use': all fields of use, save and except the SynGene Field of Use.

'SynGene Field of Use': the use of antimicrobial peptides for the creation and development of disease resistant transgenic plants.

The Licensee's four core technologies are:  Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS®), a family of advanced polymers bio-engineered to have antimicrobial, hemostatic, and other properties that can be used in a wide range of applications; Stay Fresh® is a unique chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria even after numerous laundering cycles; NimbuDerm® is a novel copolymer for application as a persistent hand sanitizer with long lasting protection against germs; and MultiStat, a family of advanced patented methods and compounds shown to be effective in skin therapy applications.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.